Lobeline for smoking cessation.

Journal article

BACKGROUND: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. OBJECTIVES: The objective of this review was to assess the effects of lobeline on long term smoking cessation. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011). SELECTION CRITERIA: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. MAIN RESULTS: We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence. AUTHORS' CONCLUSIONS: There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.

Authors: Stead, L; Hughes, JR

• Journal: Cochrane database of systematic reviews
• Volume: 2
• Pages: CD000124
• Publication date: 2012-01-01
• DOI: 10.1002/14651858.cd000124.pub2
• EISSN: 1469-493X
• Language: English
• Keywords: Nicotinic Antagonists; Smoking Cessation; Lobeline; Humans; Smoking